<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Primary Open Angle Glaucoma in Africa: Prospects and Application of Lasers in African Eyes - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjXn-31@OHwG4j-uNdngAAABk","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes","wgTitle":"Primary Open Angle Glaucoma in Africa: Prospects and Application of Lasers in African Eyes","wgCurRevisionId":80277,"wgRevisionId":80277,"wgArticleId":12105,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":
"Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes","wgRelevantArticleId":12105,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],
"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready",
"mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Glaucoma is the leading cause of irreversible blindness in the world. &amp;#91;1&amp;#93; The number of people living with glaucoma was estimated to be 64.3 million in 2013 and projected to be 76 million in 2020. &amp;#91;1&amp;#93; Glaucoma in Africans tends to be more aggressive and resistant to conventional treatments. Therefore, it was not unexpected when reported that most  blindness from glaucoma occurs in Africa.&amp;#91;2&amp;#93;Glaucoma treatment algorithms traditionally entail  initial medical therapy  followed by laser treatment  if medications fail or are inadequate to lower intraocular pressure  (IOP) to the desired level.  When laser treatment fails, surgery is often then recommended. Although there are several different types of lasers with proven efficacy, glaucoma treatment in Africa, especially in sub-Saharan Africa, largely involves a combination of medication and surgery with little or no availability of the intermediate step of laser treatment. The high cost of glaucoma medication coupled with fear of glaucoma surgery are barriers to adequate glaucoma management  in most African countries.&amp;#91;3&amp;#93; &amp;#91;4&amp;#93;"/>
<meta name="date" content="2022-04-30"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Primary Open Angle Glaucoma in Africa: Prospects and Application of Lasers in African Eyes" href="/w/index.php?title=Special:ExportRDF/Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Primary_Open_Angle_Glaucoma_in_Africa_Prospects_and_Application_of_Lasers_in_African_Eyes rootpage-Primary_Open_Angle_Glaucoma_in_Africa_Prospects_and_Application_of_Lasers_in_African_Eyes layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Primary+Open+Angle+Glaucoma+in+Africa%3A+Prospects+and+Application+of+Lasers+in+African+Eyes" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Primary+Open+Angle+Glaucoma+in+Africa%3A+Prospects+and+Application+of+Lasers+in+African+Eyes" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyzb2xv"></button>
					<div class="collapse navbar-collapse hbpzyzb2xv" id="hbpzyzb2xv">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Primary Open Angle Glaucoma in Africa: Prospects and Application of Lasers in African Eyes</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Fatima.Kyari" title="User:Fatima.Kyari">Fatima Kyari</a>,&#8201;<a href="/User:Sadiq.abdullahi" title="User:Sadiq.abdullahi">Abdullahi Sadiq</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Sadiq.abdullahi" title="User:Sadiq.abdullahi">Abdullahi Sadiq</a>,&#160;<a href="/User:Fatima.Kyari" title="User:Fatima.Kyari">Fatima Kyari</a>,&#160;<a href="/User:Arsham.Sheybani" title="User:Arsham.Sheybani">Arsham Sheybani, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Arsham.Sheybani" title="User:Arsham.Sheybani">Arsham Sheybani, MD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Update Pending</b>
</div>
</div>&#160;by <a href="/User:Arsham.Sheybani" title="User:Arsham.Sheybani">Arsham Sheybani, MD</a> on May 1, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Background"><span class="tocnumber">1</span> <span class="toctext">Background</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Patient_Selection"><span class="tocnumber">2</span> <span class="toctext">Patient Selection</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Indications"><span class="tocnumber">2.1</span> <span class="toctext">Indications</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-4"><a href="#Choice_of_Lasers"><span class="tocnumber">3</span> <span class="toctext">Choice of Lasers</span></a>
<ul>
<li class="toclevel-2 tocsection-5"><a href="#Laser_trabeculoplasty"><span class="tocnumber">3.1</span> <span class="toctext">Laser trabeculoplasty</span></a>
<ul>
<li class="toclevel-3 tocsection-6"><a href="#Argon_Laser_Trabeculoplasty_.28ALT.29"><span class="tocnumber">3.1.1</span> <span class="toctext">Argon Laser Trabeculoplasty (ALT)</span></a></li>
<li class="toclevel-3 tocsection-7"><a href="#Selective_Laser_Trabeculoplasty"><span class="tocnumber">3.1.2</span> <span class="toctext">Selective Laser Trabeculoplasty</span></a></li>
<li class="toclevel-3 tocsection-8"><a href="#Micropulse_Laser_Trabeculoplasty"><span class="tocnumber">3.1.3</span> <span class="toctext">Micropulse Laser Trabeculoplasty</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-9"><a href="#Laser_cyclophotocoagulation"><span class="tocnumber">3.2</span> <span class="toctext">Laser cyclophotocoagulation</span></a>
<ul>
<li class="toclevel-3 tocsection-10"><a href="#Transscleral_CPC"><span class="tocnumber">3.2.1</span> <span class="toctext">Transscleral CPC</span></a>
<ul>
<li class="toclevel-4 tocsection-11"><a href="#Continuous_Wave_Transscleral_CPC_.28CW-TSCPC.29"><span class="tocnumber">3.2.1.1</span> <span class="toctext">Continuous Wave Transscleral CPC (CW-TSCPC)</span></a></li>
<li class="toclevel-4 tocsection-12"><a href="#Micropulse_Transscleral_Laser_Therapy"><span class="tocnumber">3.2.1.2</span> <span class="toctext">Micropulse Transscleral Laser Therapy</span></a></li>
</ul>
</li>
<li class="toclevel-3 tocsection-13"><a href="#Endoscopic_Cyclophotocoagulation"><span class="tocnumber">3.2.2</span> <span class="toctext">Endoscopic Cyclophotocoagulation</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-14"><a href="#International_Recommendations"><span class="tocnumber">3.3</span> <span class="toctext">International Recommendations</span></a>
<ul>
<li class="toclevel-3 tocsection-15"><a href="#Laser_Trabeculoplasty_2"><span class="tocnumber">3.3.1</span> <span class="toctext">Laser Trabeculoplasty</span></a></li>
<li class="toclevel-3 tocsection-16"><a href="#Cyclophotoocoagulation"><span class="tocnumber">3.3.2</span> <span class="toctext">Cyclophotoocoagulation</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-17"><a href="#Outcomes"><span class="tocnumber">4</span> <span class="toctext">Outcomes</span></a>
<ul>
<li class="toclevel-2 tocsection-18"><a href="#IOP_Reduction"><span class="tocnumber">4.1</span> <span class="toctext">IOP Reduction</span></a></li>
<li class="toclevel-2 tocsection-19"><a href="#Impact_on_Anti-Glaucoma_Medication"><span class="tocnumber">4.2</span> <span class="toctext">Impact on Anti-Glaucoma Medication</span></a></li>
<li class="toclevel-2 tocsection-20"><a href="#Laser_as_Primary_Treatment"><span class="tocnumber">4.3</span> <span class="toctext">Laser as Primary Treatment</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-21"><a href="#Complications"><span class="tocnumber">5</span> <span class="toctext">Complications</span></a></li>
<li class="toclevel-1 tocsection-22"><a href="#Conclusion"><span class="tocnumber">6</span> <span class="toctext">Conclusion</span></a></li>
<li class="toclevel-1 tocsection-23"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Background">Background</span></h1>
<p>Glaucoma is the leading cause of irreversible blindness in the world. <sup id="cite_ref-:0_1-0" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup> The number of people living with glaucoma was estimated to be 64.3 million in 2013 and projected to be 76 million in 2020. <sup id="cite_ref-:0_1-1" class="reference"><a href="#cite_note-:0-1">&#91;1&#93;</a></sup> Glaucoma in Africans tends to be more aggressive and resistant to conventional treatments. Therefore, it was not unexpected when reported that most  blindness from glaucoma occurs in Africa.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2">&#91;2&#93;</a></sup>Glaucoma treatment algorithms traditionally entail  initial medical therapy  followed by laser treatment  if medications fail or are inadequate to lower intraocular pressure  (IOP) to the desired level.  When laser treatment fails, surgery is often then recommended. Although there are several different types of lasers with proven efficacy, glaucoma treatment in Africa, especially in sub-Saharan Africa, largely involves a combination of medication and surgery with little or no availability of the intermediate step of laser treatment. The high cost of glaucoma medication coupled with fear of glaucoma surgery are barriers to adequate glaucoma management  in most African countries.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3">&#91;3&#93;</a></sup> <sup id="cite_ref-4" class="reference"><a href="#cite_note-4">&#91;4&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Patient_Selection">Patient Selection</span></h1>
<p>Generally, any patient diagnosed with primary open angle glaucoma (POAG) may benefit from laser treatment especially  when the target IOP cannot be achieved with  medical therapy. Recently, it has been shown that selective laser trabeculoplasty is  effective as primary treatment when compared to medicines. Other forms of secondary glaucoma such as pseudoexfoliation or pigmentary glaucoma could also benefit from laser trabeculoplasty. However, laser trabeculoplasty is contraindicated in synechial angle closure glaucoma, neovascular glaucoma, patients with corneal opacity, ICE syndrome, and congenital glaucoma. With the improved  safety profile of laser cyclophotocoagulation, micropulse transscleral laser therapy is now being  used in treating eyes with good vision.
</p>
<div class="thumb tright"><div class="thumbinner" style="width:302px;"><a href="/File:IMG_8782.jpeg" class="image"><img alt="" src="/w/images/1/thumb/6/6d/IMG_8782.jpeg/300px-IMG_8782.jpeg" decoding="async" width="300" height="400" class="thumbimage" srcset="/w/images/1/thumb/6/6d/IMG_8782.jpeg/450px-IMG_8782.jpeg 1.5x, /w/images/1/thumb/6/6d/IMG_8782.jpeg/600px-IMG_8782.jpeg 2x" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/File:IMG_8782.jpeg" class="internal" title="Enlarge"></a></div>Dr A Sadiq performing MLT in Nigeria</div></div></div>
<h2><span class="mw-headline" id="Indications">Indications</span></h2>
<ol><li>Adjuvant treatment of POAG</li>
<li>Primary Treatment of POAG</li>
<li>Treatment of some secondary open angle glaucomas</li>
<li>Treatment of refractory glaucomas</li>
<li>Treatment of failed glaucoma surgery</li>
<li>Treatment of pediatric glaucoma</li>
<li>Suture lysis post-trabeculectomy</li>
<li>Poor compliance with eye drop regimens</li>
<li>Difficulty using eye drops due to intolerance</li></ol>
<h1><span class="mw-headline" id="Choice_of_Lasers">Choice of Lasers</span></h1>
<h2><span class="mw-headline" id="Laser_trabeculoplasty">Laser trabeculoplasty</span></h2>
<p>This is defined as application of laser to trabecular meshwork in order to improve facility of aqueous outflow. Wiser and Witter in 1979 introduced Argon Laser Trabeculoplasty (ALT) while Latina and Park described selective laser trabeculoplasty (SLT) in 1995.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">&#91;5&#93;</a></sup> <sup id="cite_ref-:1_6-0" class="reference"><a href="#cite_note-:1-6">&#91;6&#93;</a></sup>Several studies have demonstrated the efficacy and safety of the two procedures. <sup id="cite_ref-:2_7-0" class="reference"><a href="#cite_note-:2-7">&#91;7&#93;</a></sup><sup id="cite_ref-:3_8-0" class="reference"><a href="#cite_note-:3-8">&#91;8&#93;</a></sup>Micropulse Laser Trabeculoplasty (MLT) is the newest addition into the armamentarium<sup id="cite_ref-:4_9-0" class="reference"><a href="#cite_note-:4-9">&#91;9&#93;</a></sup>
</p>
<h3><span id="Argon_Laser_Trabeculoplasty_(ALT)"></span><span class="mw-headline" id="Argon_Laser_Trabeculoplasty_.28ALT.29">Argon Laser Trabeculoplasty (ALT)</span></h3>
<p>This was first introduced in 1979 and it involves application of CW 514nm argon green or blue-green laser at the junction between the pigmented and non-pigmented portion of the trabecular meshwork. ALT brings about IOP reduction via creating some mechanical changes in trabecular meshwork that subsequently open up the drainage pathway or by stimulating biological activity in trabecular cells that leads to IOP reduction. The safety and efficacy of the laser has been reported in several studies.<sup id="cite_ref-:2_7-1" class="reference"><a href="#cite_note-:2-7">&#91;7&#93;</a></sup>,<sup id="cite_ref-10" class="reference"><a href="#cite_note-10">&#91;10&#93;</a></sup><sup id="cite_ref-11" class="reference"><a href="#cite_note-11">&#91;11&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Selective_Laser_Trabeculoplasty">Selective Laser Trabeculoplasty</span></h3>
<p>Introduced in 1995 this technique uses Q-switched ND-YAG and frequency-doubled ND YAG laser at pulse duration of 10 nanoseconds to 1 microseconds selectively targeting pigmented portion of trabecular meshwork without collateral damage to adjacent tissues. SLT is thought to reduce IOP by stimulating cascade of cellular activities in trabecular meshwork that ultimately leads to increase facility of aqueous outflow.<sup id="cite_ref-:1_6-1" class="reference"><a href="#cite_note-:1-6">&#91;6&#93;</a></sup><sup id="cite_ref-:7_12-0" class="reference"><a href="#cite_note-:7-12">&#91;12&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Micropulse_Laser_Trabeculoplasty">Micropulse Laser Trabeculoplasty</span></h3>
<p>With this technique instead of delivering the laser energy in a continuous wave, the energy is subdivided into short pulses with specific “on” and “off” times thereby minimizing the heat buildup and hence thermal damage to adjacent tissues. The off interlude allows the temperature of the target tissue to cool down before the next shot .It also fend off spread of energy to adjacent tissue.<sup id="cite_ref-:4_9-1" class="reference"><a href="#cite_note-:4-9">&#91;9&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Laser_cyclophotocoagulation">Laser cyclophotocoagulation</span></h2>
<p>This is the use of laser energy to destroy ciliary processes. The energy absorbed by pigmented epithelium of the ciliary body leads to coagulative necrosis of the tissue and subsequent reduction in aqueous production. Cyclophotocoagulation can be achieved with an Nd-YAG or diode laser. Currently, Diode Laser Cyclophotocoagulation has supplanted Nd-YAG CPC and it can be either Transscleral Diode Laser Cyclophocoagulation (TSCPC) or Endoscopic Cyclophocoagulation (ECP).<sup id="cite_ref-:5_13-0" class="reference"><a href="#cite_note-:5-13">&#91;13&#93;</a></sup> 
</p>
<h3><span class="mw-headline" id="Transscleral_CPC">Transscleral CPC</span></h3>
<p>Transscleral CPC employs a specifically designed probe contact plate and when placed at the appropriate distance from the limbus ensures delivery of energy into the ciliary processes.  Laser CPC is a treatment of last resort reserved for glaucoma unresponsive to maximum medical treatment, eyes that have failed filtration surgery or are likely to fail future filtration surgery such as aphakic glaucoma, neovascular glaucoma etc. Transscleral CPC could be performed with either continuous wave or micropulse diode laser.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">&#91;14&#93;</a></sup>
</p>
<h4><span id="Continuous_Wave_Transscleral_CPC_(CW-TSCPC)"></span><span class="mw-headline" id="Continuous_Wave_Transscleral_CPC_.28CW-TSCPC.29">Continuous Wave Transscleral CPC (CW-TSCPC)</span></h4>
<p>The CW-TSCPC delivers continuous laser energy to the ciliary epithelium. Although it has been shown to be effective in treatment of refractory glaucoma, the reported  side effects such as hypotony and phthisis imputed to the continuous laser delivery limits its utility in eyes with good vision. 
</p>
<h4><span class="mw-headline" id="Micropulse_Transscleral_Laser_Therapy">Micropulse Transscleral Laser Therapy</span></h4>
<p>This improves the safety profile of the procedure in that it releases energy in a form of repetitive pulses on interspersed with pulses off cycle.<sup id="cite_ref-:5_13-1" class="reference"><a href="#cite_note-:5-13">&#91;13&#93;</a></sup> <sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup>The off interlude allows the target tissue to cool down and also prevents dissipation of energy to the adjacent tissue.
</p>
<h3><span class="mw-headline" id="Endoscopic_Cyclophotocoagulation">Endoscopic Cyclophotocoagulation</span></h3>
<p>This involves direct application of the laser to the targeted ciliary pigmented epithelium with little or no collateral damage to the adjacent ciliary muscle, ciliary body stroma or par plana and it can be combined with cataract surgery.
</p>
<h2><span class="mw-headline" id="International_Recommendations">International Recommendations</span></h2>
<p>These recommendations are from the <a rel="nofollow" class="external text" href="http://www.icoph.org/downloads/ICOGlaucomaGuidelines.pdf">International Council of Ophthalmology (ICO) Guidelines for Glaucoma Care.</a>
</p>
<h3><span class="mw-headline" id="Laser_Trabeculoplasty_2">Laser Trabeculoplasty</span></h3>
<table class="wikitable">
<caption>
</caption>
<tbody><tr>
<th>Treatment Parameters
</th>
<th>Argon Laser Trabeculoplasty
</th>
<th>Selective Laser Trabeculoplasty
</th></tr>
<tr>
<td>Laser type
</td>
<td>Argon green or Blue green/Diode Laser
</td>
<td>Frequency doubled Q-Switched Nd:YaG Laser(532nm)
</td></tr>
<tr>
<td>Spot size
</td>
<td>50 microns (Argon) or 75 microns (Diode)
</td>
<td>40 microns
</td></tr>
<tr>
<td>Power
</td>
<td>300 to 1000mW
</td>
<td>0.5 to 2mJ
</td></tr>
<tr>
<td>Application site
</td>
<td>TM junction non-pigmented/pigment
</td>
<td>Trabecular meshwork (TM)
</td></tr>
<tr>
<td>Handheld Lens
</td>
<td>Goldmann gonioscopy lens or Ritch lens
</td>
<td>Goldman or SLT lens
</td></tr>
<tr>
<td>Treated Circumferance
</td>
<td>180-360
</td>
<td>180-360
</td></tr>
<tr>
<td>Number of Burns
</td>
<td>50 per 180 degrees
</td>
<td>50 per 180 degrees
</td></tr>
<tr>
<td>Number of Settings
</td>
<td>1 or 2
</td>
<td>
</td></tr>
<tr>
<td>End points
</td>
<td>Blanching at junction of anterior non-pigmented and pigmented TM&#160;
</td>
<td>
</td></tr></tbody></table>
<div class="thumb tright"><div class="thumbinner" style="width:302px;"><a href="/File:IMG_4266.jpeg" class="image"><img alt="" src="/w/images/1/thumb/c/c5/IMG_4266.jpeg/300px-IMG_4266.jpeg" decoding="async" width="300" height="400" class="thumbimage" srcset="/w/images/1/thumb/c/c5/IMG_4266.jpeg/450px-IMG_4266.jpeg 1.5x, /w/images/1/thumb/c/c5/IMG_4266.jpeg/600px-IMG_4266.jpeg 2x" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/File:IMG_4266.jpeg" class="internal" title="Enlarge"></a></div>Dr A Sadiq performing TSCPC in Nigeria</div></div></div>
<h3><span class="mw-headline" id="Cyclophotoocoagulation">Cyclophotoocoagulation</span></h3>
<table class="wikitable">
<tbody><tr>
<th>Treatment Parameters
</th>
<th><b>Transscleral Diode Laser&#160;</b>
</th></tr>
<tr>
<td>Laser Type
</td>
<td>Diode Laser&#160;
</td></tr>
<tr>
<td>Power
</td>
<td>1.0 to 2.5 W&#160;
</td></tr>
<tr>
<td>Exposure Time
</td>
<td>0.5 to 4.0 seconds&#160;
</td></tr>
<tr>
<td>Application Site&#160;
</td>
<td>1.0 to 2.0 mm from limbus&#160;
</td></tr>
<tr>
<td>Handheld Probe&#160;
</td>
<td>Transscleral contact&#160;
</td></tr>
<tr>
<td>Treated Circumference&#160;
</td>
<td>180 – 360 degrees&#160;
</td></tr>
<tr>
<td>Number of Burns&#160;
</td>
<td>~ 12 – 20 spots per 180 degrees&#160;
</td></tr>
<tr>
<td>Number of Sittings&#160;
</td>
<td>1 or 2&#160;
</td></tr></tbody></table>
<h1><span class="mw-headline" id="Outcomes">Outcomes</span></h1>
<h2><span class="mw-headline" id="IOP_Reduction">IOP Reduction</span></h2>
<p>Selective laser trabeculoplasty has been shown to be effective in IOP reduction, and the percentage of IOP reduction as well as the mean IOP decrease varies between studies.<sup id="cite_ref-:1_6-2" class="reference"><a href="#cite_note-:1-6">&#91;6&#93;</a></sup>,<sup id="cite_ref-16" class="reference"><a href="#cite_note-16">&#91;16&#93;</a></sup><sup id="cite_ref-17" class="reference"><a href="#cite_note-17">&#91;17&#93;</a></sup><sup id="cite_ref-:6_18-0" class="reference"><a href="#cite_note-:6-18">&#91;18&#93;</a></sup> In South Africa, Goosen et al <sup id="cite_ref-19" class="reference"><a href="#cite_note-19">&#91;19&#93;</a></sup>reported 32.0% (20mmHg to 13.6mmHg) IOP reduction from baseline and observed no difference in response between male and female patients. Similarly, Seck et al<sup id="cite_ref-20" class="reference"><a href="#cite_note-20">&#91;20&#93;</a></sup> retrospectively reviewed 69 eyes of  40 black patients 12 months after treatment with SLT. The results showed that 90% of patients had a mean IOP decrease of 2.3 ± 1 mmHg and SLT permitted discontinuation of a prostaglandin in 60% (42 cases). Similarly, Micropulse Laser Trabeculoplasty has also been shown to cause 17.2% reduction from baseline among Nigerian eyes.<sup id="cite_ref-:6_18-1" class="reference"><a href="#cite_note-:6-18">&#91;18&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Impact_on_Anti-Glaucoma_Medication">Impact on Anti-Glaucoma Medication</span></h2>
<p>Glaucoma patients incur financial burden as well as side effects as result of prolonged use of anti-glaucoma medication. Ahmed et al <sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup> found significant reduction in anti-glaucoma medication from 2.25 ± 0.97 before SLT treatment  to 1.0 (±1.3) at the end of 18 months follow-up (P= 0.004). 
</p>
<h2><span class="mw-headline" id="Laser_as_Primary_Treatment">Laser as Primary Treatment</span></h2>
<p>The seminal LiGHT trial<sup id="cite_ref-:3_8-1" class="reference"><a href="#cite_note-:3-8">&#91;8&#93;</a></sup>, though not conducted on African eyes, described how target intraocular pressure was achieved without intraocular pressure medication in 419 (78·2%) of 536 eyes treated with selective laser trabeculoplasty as primary treatment. Additionally, in Nigeria, Abdul et al <sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup>demonstrated that  83% of POAG had a drop in IOP of &gt;30% at 12 months after primary treatment with continuous trans-scleral cyclophotocoagulation and only 9% were on medication at the final follow up.
</p>
<h1><span class="mw-headline" id="Complications">Complications</span></h1>
<p>Complications  associated with laser trabeculoplasty include acute IOP elevation, uveitis, peripheral anterior synechia, corneal burns and hyphema, <sup id="cite_ref-:7_12-1" class="reference"><a href="#cite_note-:7-12">&#91;12&#93;</a></sup>while transscleral cyclophotocoagulation complications include hyptony, decreased vision, phthisis and severe inflammation.<sup id="cite_ref-:5_13-2" class="reference"><a href="#cite_note-:5-13">&#91;13&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Conclusion">Conclusion</span></h1>
<p>Given the huge annual cost of glaucoma medication in sub-Saharan Africa<sup id="cite_ref-23" class="reference"><a href="#cite_note-23">&#91;23&#93;</a></sup> and  the proven efficacy of laser procedures for the treatment of POAG, laser treatments should be encouraged and be made more  available and affordable to glaucoma caregivers in Africa.
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-:0-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:0_1-0">1.0</a></sup> <sup><a href="#cite_ref-:0_1-1">1.1</a></sup></span> <span class="reference-text"><span lang="EN-GB">&#160; &#160; &#160; &#160; &#160; &#160;&#160;Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis.&#160;<i>Ophthalmology</i>. 2014;121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013</span></span>
</li>
<li id="cite_note-2"><span class="mw-cite-backlink"><a href="#cite_ref-2">↑</a></span> <span class="reference-text"><span lang="EN-GB">Kyari F, Abdull MM, Bastawrous A, Gilbert CE, Faal H. Epidemiology of glaucoma in sub-saharan Africa: prevalence, incidence and risk factors.&#160;<i>Middle East Afr J Ophthalmol</i>. 2013;20(2):111-125. doi:10.4103/0974-9233.110605</span></span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><a href="#cite_ref-3">↑</a></span> <span class="reference-text"><span lang="EN-GB">Ad koya BJ, Akinsola FB, Balogun BG, Balogun MM, Ibidapo OO. Patient refusal of glaucoma surgery and associated factors in Lagos, Nigeria.&#160;<i>Middle East Afr J Ophthalmol</i>. 2013;20(2):168-173. doi:10.4103/0974-9233.110612e</span></span>
</li>
<li id="cite_note-4"><span class="mw-cite-backlink"><a href="#cite_ref-4">↑</a></span> <span class="reference-text"><span lang="EN-GB">Adio AO, Onua AA. Economic burden of glaucoma in Rivers State, Nigeria.&#160;<i>Clin Ophthalmol</i>. 2012;6:2023-2031. doi:10.2147/OPTH.S37145</span></span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><a href="#cite_ref-5">↑</a></span> <span class="reference-text"><span lang="EN-GB">James B, Witter SL. A Pilot Glaucoma.&#160;<i>ArchOphthalmol</i>. 1979;97:319-322.</span></span>
</li>
<li id="cite_note-:1-6"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:1_6-0">6.0</a></sup> <sup><a href="#cite_ref-:1_6-1">6.1</a></sup> <sup><a href="#cite_ref-:1_6-2">6.2</a></sup></span> <span class="reference-text"><span lang="EN-GB">Latina MA, Park C. Selective targeting of trabecular meshwork cells: In vitro studies of pulsed and CW laser interactions.&#160;<i>Exp Eye Res</i>. 1995;60(4):359-371. doi:10.1016/S0014-4835(05)80093-4</span></span>
</li>
<li id="cite_note-:2-7"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:2_7-0">7.0</a></sup> <sup><a href="#cite_ref-:2_7-1">7.1</a></sup></span> <span class="reference-text"><span lang="EN-GB">Investigators TA. The advanced glaucoma intervention study (AGIS): 1. Study design and methods and baseline characteristics of study patients.&#160;<i>Control Clin Trials</i>. 1994;15(4):299-325. doi:10.1016/0197-2456(94)90046-9</span></span>
</li>
<li id="cite_note-:3-8"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:3_8-0">8.0</a></sup> <sup><a href="#cite_ref-:3_8-1">8.1</a></sup></span> <span class="reference-text"><span lang="EN-GB">Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.&#160;<i>Lancet</i>. 2019;393(10180):1505-1516. doi:10.1016/S0140-6736(18)32213-X</span></span>
</li>
<li id="cite_note-:4-9"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:4_9-0">9.0</a></sup> <sup><a href="#cite_ref-:4_9-1">9.1</a></sup></span> <span class="reference-text"><span lang="EN-GB">Ma A, Yu SWY, Wong JKW. Micropulse laser for the treatment of glaucoma: A literature review.&#160;<i>Surv Ophthalmol</i>. 2019;64(4):486-497. doi:10.1016/j.survophthal.2019.01.001</span></span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><a href="#cite_ref-10">↑</a></span> <span class="reference-text"><span lang="EN-GB">Krug J, Chiavelli M, Borawski G, et al. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results.&#160;<i>Am J Ophthalmol</i>. 1995;120(6):718-731. doi:10.1016/s0002-9394(14)72725-4</span></span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><a href="#cite_ref-11">↑</a></span> <span class="reference-text"><span lang="EN-GB">Wilensky JT, Jampol LM. Laser Therapy for Open Angle Glaucoma.&#160;<i>Ophthalmology</i>. 1981;88(3):213-217. doi:10.1016/S0161-6420(81)35047-7</span></span>
</li>
<li id="cite_note-:7-12"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:7_12-0">12.0</a></sup> <sup><a href="#cite_ref-:7_12-1">12.1</a></sup></span> <span class="reference-text"><span lang="EN-GB">Garg A, Gazzard G. Selective laser trabeculoplasty: Past, present, and future review-article.&#160;<i>Eye</i>. 2018;32(5):863-876. doi:10.1038/eye.2017.273</span></span>
</li>
<li id="cite_note-:5-13"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:5_13-0">13.0</a></sup> <sup><a href="#cite_ref-:5_13-1">13.1</a></sup> <sup><a href="#cite_ref-:5_13-2">13.2</a></sup></span> <span class="reference-text"><span lang="EN-GB">&#160; &#160; &#160; &#160; &#160; &#160;&#160;Dastiridou AI, Katsanos A, Denis P, et al. Cyclodestructive Procedures in Glaucoma: A Review of Current and Emerging Options.&#160;<i>Adv Ther</i>. 2018;35(12):2103-2127. doi:10.1007/s12325-018-0837-3</span></span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><a href="#cite_ref-14">↑</a></span> <span class="reference-text"><span lang="EN-GB">Abdelrahman AM, El Sayed YM. Micropulse Versus Continuous Wave Transscleral Cyclophotocoagulation in Refractory Pediatric Glaucoma.&#160;<i>J Glaucoma</i>. 2018;27(10):900-905. doi:10.1097/IJG.0000000000001053</span></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><a href="#cite_ref-15">↑</a></span> <span class="reference-text"><span lang="EN-GB">Hirabayashi MT, Rosenlof TL, An JA. Comparison of Successful outcome Predictors for MicroPulse® Laser Trabeculoplasty and Selective Laser Trabeculoplasty at 6 months.&#160;<i>Clin Ophthalmol</i>. 2019;13:1001-1009. doi:10.2147/OPTH.S205977</span></span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><a href="#cite_ref-16">↑</a></span> <span class="reference-text"><span lang="EN-GB">Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: Results from a 1-year randomised clinical trial.&#160;<i>Br J Ophthalmol</i>. 2006;90(12):1490-1494. doi:10.1136/bjo.2006.098855</span></span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><a href="#cite_ref-17">↑</a></span> <span class="reference-text"><span lang="EN-GB">Onakoya AO, Olowoyeye AO, Onyekwelu OMA, Abikoye TM. Intraocular Pressure Changes Post Selective Laser Trabeculoplasty in the Contralateral Untreated Eyes of Nigerian Patients With Primary Open Angle Glaucoma.&#160;<i>Nig Q J Hosp Med</i>. 2015;25(2):133-138.</span></span>
</li>
<li id="cite_note-:6-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:6_18-0">18.0</a></sup> <sup><a href="#cite_ref-:6_18-1">18.1</a></sup></span> <span class="reference-text"><span lang="EN-GB">Babalola OE. Micropulse diode laser trabeculoplasty in nigerian patients.&#160;<i>Clin Ophthalmol</i>. 2015;9:1347-1351. doi:10.2147/OPTH.S82678</span></span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><a href="#cite_ref-19">↑</a></span> <span class="reference-text"><span lang="EN-GB">Goosen E, Coleman K, Visser L, Sponsel WE. Racial Differences in Selective Laser Trabeculo-plasty Efficacy.&#160;<i>J Curr Glaucoma Pr</i>. 2017;11(1):22-27. doi:10.5005/jp-journals-10008-1216</span></span>
</li>
<li id="cite_note-20"><span class="mw-cite-backlink"><a href="#cite_ref-20">↑</a></span> <span class="reference-text"><span lang="EN-GB">Seck SM, Agboton G, Dieng M, et al. La trabéculoplastie au laser sélectif (TLS): notre expérience chez le noir africain.&#160;<i>J Fr Ophtalmol</i>. 2015;38(3):238-246. doi:10.1016/j.jfo.2014.11.002</span></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><a href="#cite_ref-21">↑</a></span> <span class="reference-text"><span lang="EN-GB">Abdelrahman A, Eltanamly R. Selective laser trabeculoplasty in Egyptian patients with primary open-angle glaucoma.&#160;<i>Middle East Afr J Ophthalmol</i>. 2012;19(3):299-303. doi:10.4103/0974-9233.97930</span></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><a href="#cite_ref-22">↑</a></span> <span class="reference-text"><span lang="EN-GB">Abdull MM, Broadway DC, Evans J, Kyari F, Muazu F, Gilbert C. Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria.&#160;<i>Clin Exp Ophthalmol</i>. 2018;46(9):1041-1047. doi:10.1111/ceo.13328</span></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><a href="#cite_ref-23">↑</a></span> <span class="reference-text"><span lang="EN-GB">AF S, G N, A M, et al. Glaucoma Control Strategies in Sub-Saharan Africa: A Review of the Clinical and Health Economic Evidence.&#160;<i>Ophthalmic Epidemiol</i>. 2018;25(5-6). doi:10.1080/09286586.2018.1501499</span></span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035200
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.016 seconds
CPU time usage: 0.187 seconds
Real time usage: 1.703 seconds
Preprocessor visited node count: 800/1000000
Post‐expand include size: 6419/2097152 bytes
Template argument size: 1279/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 11977/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  742.990      1 Template:Article
100.00%  742.990      1 -total
 87.01%  646.471      4 Template:Infobox_section
 37.13%  275.849      7 Template:UserLookup
  6.52%   48.423      1 Template:Review_expired
  3.39%   25.204      1 Template:Get_active_contest
  3.27%   24.265      1 Template:Infobox_end
  0.13%    0.938      1 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;oldid=80277">https://eyewiki.org/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;oldid=80277</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyzbksm">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;oldid=80277" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Primary_Open_Angle_Glaucoma_in_Africa:_Prospects_and_Application_of_Lasers_in_African_Eyes&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on May 3, 2022, at 08:15.</div>
					<div>This page has been accessed 7,105 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.016},"limitreport":{"cputime":"0.187","walltime":"1.703","ppvisitednodes":{"value":800,"limit":1000000},"postexpandincludesize":{"value":6419,"limit":2097152},"templateargumentsize":{"value":1279,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":11977,"limit":5000000},"timingprofile":["100.00%  742.990      1 Template:Article","100.00%  742.990      1 -total"," 87.01%  646.471      4 Template:Infobox_section"," 37.13%  275.849      7 Template:UserLookup","  6.52%   48.423      1 Template:Review_expired","  3.39%   25.204      1 Template:Get_active_contest","  3.27%   24.265      1 Template:Infobox_end","  0.13%    0.938      1 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035200","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":2516});});</script></body>
</html>